It was previously reported that when exploring immunotherapy outcomes for NSCLC patients concerning TMB, the consensus was that elevated TMB levels are analogous to high levels of PD-L1, yielding improved results and heightened responsiveness to immunotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.